Karuna Therapeutics Inc expected to post a loss of $2.73 a share - Earnings Preview

Karuna Therapeutics

02/05/2023 19:25

* Karuna Therapeutics Inc  KRTX.OQ   KRTX.O  is expected
to show
no change in quarterly revenue when it reports  results on May
4. 
    * 
    * ​Refinitiv's mean analyst estimate for Karuna Therapeutics
Inc
is for a loss of $2.73 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 20 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Karuna
Therapeutics Inc is $280​, above​ its last closing price
of $205.11. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -2.37       -2.25      -2.22     Beat    1.2
 Sep. 30 2022  -2.13       -2.13      -2.38     Missed  -11.5
 Jun. 30 2022  -2.04       -2.09      -2.17     Missed  -3.6​
 Mar. 31 2022  -2.18       -2.11      -1.95     Beat    7.6
 ​​Dec.        -1.66       -1.73      -0.94     Beat    45.8
 31 2021                                                
 Sep. 30 2021  -1.45       -1.44      -1.72     Missed  -19.4​
 Jun. 30 2021  -1.30       -1.34      -1.17     Beat    12.5
 Mar. 31 2021  -1.16       -1.13      -1.07     Beat    5.4
 This summary was machine generated May 2 at 18:25 GMT.  All
figures in US dollars  unless otherwise stated